SYNIMMUNE GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a special focus on orphan hematopoietic malignancies.
SYNIMMUNE's lead product FLYSYN is a monoclonal antibody for the treatment of acute myeloid leukemia (AML). In addtion to its specificity for FLT3, a surface protein which is mainly expressed on leukemic blast cells, FLYSYN contains a genetic optimization of its Fc part, which provides for substantially increased binding to natural killer (NK) cells and consequently results in improved antibody dependent cell-mediated cytotoxicity (ADCC) and stronger killing of tumor cells. FLYSYN is currently tested in a first-in-man study in AML patients with minimal residual disease.
SYNIMMUNE also develops antibodies based on a proprietary, patent protected platform for bispecific antibodies, which are characterized by good producibility, improved stability and neglegible formation of aggregates and therefore no off-target activity.
SYNIMMUNE GmbH is a spin-off from the University of Tübingen and was supported by the German Federal Ministry for Education and Research (BMBF) in the course of its GO-Bio initiative and received funding from the German KfW and private investors.
Further information on the websites of BIOPRO Baden-Württemberg: